Halozyme Therapeutics Earnings, Sales Surge in Q1
04:27 PM EDT, 05/10/2021 (MT Newswires) -- Halozyme Therapeutics (HALO) reported Q1 adjusted earnings per share of $0.37, up from $0.02 a year ago.
Analysts polled by Capital IQ had expected earnings of $0.32 per share.
Sales rose to $89 million from $25.4 million a year earlier. Analysts surveyed by Capital IQ had projected revenue of $84.9 million.
For full-year 2021, the company expects adjusted EPS to be in the range of $1.55 to $1.70, which compares with a market projection compiled by Capital IQ of $1.55.
Price: 45.00, Change: -1.10, Percent Change: -2.39